Drug Information

Drug General Information
Drug ID
D0A6VD
Former ID
DIB015884
Drug Name
VS-4718
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [524282]
Company
Verastem
Target and Pathway
Target(s) Focal adhesion kinase Target Info Inhibitor [532800]
KEGG Pathway ErbB signaling pathway
Chemokine signaling pathway
PI3K-Akt signaling pathway
Axon guidance
VEGF signaling pathway
Focal adhesion
Leukocyte transendothelial migration
Regulation of actin cytoskeleton
Bacterial invasion of epithelial cells
Amoebiasis
Pathways in cancer
Transcriptional misregulation in cancer
Proteoglycans in cancer
Small cell lung cancer
PANTHER Pathway Angiogenesis
Integrin signalling pathway
VEGF signaling pathway
CCKR signaling map ST
Pathway Interaction Database LPA receptor mediated events
CXCR4-mediated signaling events
Reactome Apoptotic cleavage of cellular proteins
Regulation of actin dynamics for phagocytic cup formation
Integrin alphaIIb beta3 signaling
GRB2:SOS provides linkage to MAPK signaling for Integrins
p130Cas linkage to MAPK signaling for integrins
NCAM signaling for neurite out-growth
Signal regulatory protein (SIRP) family interactions
EPHB-mediated forward signaling
EPHA-mediated growth cone collapse
DCC mediated attractive signaling
Netrin mediated repulsion signals
VEGFA-VEGFR2 Pathway
RHO GTPases Activate WASPs and WAVEs
RAF/MAP kinase cascade
WikiPathways Regulation of Actin Cytoskeleton
EGF/EGFR Signaling Pathway
TGF beta Signaling Pathway
Signaling of Hepatocyte Growth Factor Receptor
Focal Adhesion
Apoptosis-related network due to altered Notch3 in ovarian cancer
Nanoparticle-mediated activation of receptor signaling
JAK/STAT
Primary Focal Segmental Glomerulosclerosis FSGS
Alpha 6 Beta 4 signaling pathway
Corticotropin-releasing hormone
Leptin signaling pathway
RANKL/RANK Signaling Pathway
Netrin-1 signaling
NCAM signaling for neurite out-growth
Integrin-mediated Cell Adhesion
Integrin alphaIIb beta3 signaling
Apoptotic execution phase
Angiogenesis
Androgen receptor signaling pathway
References
Ref 524282ClinicalTrials.gov (NCT01849744) Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies. U.S. National Institutes of Health.
Ref 532800FAK Inhibition disrupts a beta5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther. 2014 Aug;13(8):2050-61.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.